Organoleptic Evaluation, User Acceptability, and Cosmetic Safety of Physiorelax Forte Plus Formulations in a Pediatric Population

Massage relieves stress and anxiety, but also helps to reduce musculoskeletal problems, decreasing tension, in all stages of life. For pediatric use, organoleptic properties, cosmetic safety and user acceptability of topical products are important given the higher frequency of irritative or allergic episodes in young skin. We evaluate for the first time the comprehensive cosmetic performance of Physiorelax Forte Plus natural formulation in cream, spray and roll-on applied regularly in healthy and active children/adolescents. 210 healthy volunteers were included (150 adults with sensitive skin and 60 children and adolescents 6–16 years). This three-part, sequential, observational, non-comparative pilot design monitored user experience under real-world conditions: (I) Open-label testing to assess skin compatibility in adults (N = 60); (II) In-use testing in adults for cosmetic acceptability and safety over 14 days (N = 90); (III) In-use testing in children/adolescents for 14 days (N = 60). Outcomes were dermatological assessments for tolerability and user (and/or parents/caregiver(s)-reported) satisfaction/acceptability and perceived benefits. No control group or objective efficacy measures were included. Among pediatric participants, no cutaneous reactions were observed at application sites after 14 days of use. Proxy reporting about consumer satisfaction and acceptability for the range were generally high. Principal component analysis revealed a clear three-cluster structure (sensory, functional, practicality), with roll-on driving the strongest differentiation across items and spray aligning most closely with sensory attributes, while cream showed an intermediate functional profile. The Physiorelax Forte Plus range demonstrated a favorable cosmetic safety profile and consumer acceptability in pediatric use under real-world conditions. Findings are limited by the observational, unblinded design, absence of a control group, and reliance on subjectively reported outcomes; no clinical or pharmaceutical claims are implied. Future controlled studies incorporating objective dermatologic endpoints, benchmark products, and direct child/adolescent reporting are warranted.